Can Cytokines Predict the Severity of Acute Mucositis and the Need for Gastrostomy Tubes (PEG)?
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Mucositis and xerostomia are the most common complications of head and neck (H&N) irradiation, and the combination of chemotherapy and radiation therapy is associated with a significantly higher rate of complications.
Mucositis usually develops during the second or third week of a course of standard radiotherapy, and the pain it causes peaks between the third and last week of treatment. The pain then persists for at least one month following the completion of therapy, and may be so overwhelming that it prevents patients from swallowing food and fluids. The patient is therefore at a risk to develop malnutrition, and must be treated vigorously. In this respect, the use of gastrostomy tubes (PEG) has been shown to be beneficial.
Completion of the full course of irradiation, without interruption, is important for achieving best possible results in cancer of the H&N. It is therefore essential to identify and refer patients at risk to receive effective and timely nutritional intervention.
Since mucositis represents a clinical continuum which differs between patients, it is difficult to assess before-hand which patients will be at risk.
There is no simple laboratory tool available, which could predict which patients are susceptible to develop severe mucositis and dysphagia, and eventually will require a feeding gastrostomy.
The first phase of mucositis, inflammation, results in the production of pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α).
In general, the inflammatory cytokines IL-1, interleukin-6 (IL-6) and TNF-α are elevated in inflammatory conditions and are found in increased levels in blood and tissue fluid during inflammation, while anti-inflammatory cytokines are produced in a decreased manner.
The main purpose of this study is to find the best indicators and prognosticators of mucositis occurring in the healthy oral tissues of H&N cancer patients receiving treatment, and to understand the cytokines balance mechanism of action.
Assuming there is a correlation between high cytokines levels during inflammation and the severity of radiation induced mucositis, finding these prognostic factors may help us predict during the first part of the treatment the need for PEG, placing it prior to the complications associated with severe mucositis on one hand, and avoiding unnecessary procedures on the other hand.
| Condition |
|---|
|
Oral Mucositis Xerostomia Weight Loss Head and Neck Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Observational Model: Natural History Time Perspective: Longitudinal Time Perspective: Prospective |
| Official Title: | Can Cytokines Predict the Severity of Acute Mucositis and the Need for PEG During Chemo-Radiation Treatment to Head and Neck Cancer? |
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with H&N epithelial cancer (nasopharynx, oropharynx, oral cavity - tongue, buccal mucosae and palate, larynx and hypopharynx)
- Treated with definitive chemo-radiation treatment and follow up
- Male and female patients will be included, with an age ranging between 18- 85 years
Exclusion Criteria:
- Soldiers, prisoners and pregnant women will be excluded.
Contacts and Locations| Contact: Arik Tzukert, DMD | 00 972 2 6777111 | arik@hadassah.org.il |
| Israel | |
| Hadassah Medical Organization | |
| Jerusalem, Israel, 91120 | |
| Principal Investigator: | Amichay Meirovitz, MD | Hadassah Medical Organization |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00431925 History of Changes |
| Other Study ID Numbers: | MucoCyt- HMO-CTIL |
| Study First Received: | February 5, 2007 |
| Last Updated: | August 9, 2007 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Hadassah Medical Organization:
|
head and neck cancer radiation therapy chemotherapy mucositis |
cytokines gastrostomy radiotherapy |
Additional relevant MeSH terms:
|
Xerostomia Head and Neck Neoplasms Stomatitis Weight Loss Mucositis Neoplasms by Site Neoplasms Mouth Diseases |
Stomatognathic Diseases Body Weight Changes Body Weight Signs and Symptoms Salivary Gland Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on June 18, 2013